CO6140054A2 - Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico - Google Patents

Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico

Info

Publication number
CO6140054A2
CO6140054A2 CO08115666A CO08115666A CO6140054A2 CO 6140054 A2 CO6140054 A2 CO 6140054A2 CO 08115666 A CO08115666 A CO 08115666A CO 08115666 A CO08115666 A CO 08115666A CO 6140054 A2 CO6140054 A2 CO 6140054A2
Authority
CO
Colombia
Prior art keywords
dialquilphenyl
compounds
receptor agonist
adrenergic receptor
agonist activity
Prior art date
Application number
CO08115666A
Other languages
English (en)
Inventor
Pierre-Jean Colson
Adam Hughes
Craig Husfeld
Mathai Mammen
Miroslav Rapta
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CO6140054A2 publication Critical patent/CO6140054A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1.- Un compuesto de fórmula I:CARACTERIZADO PORQUE R1 es metilo o etilo; R2 es metilo o etilo; o una sal o solvato o estereoisómero del mismo aceptable para uso farmacéutico. 2.- Un compuesto de la reivindicación 1 con fórmula II:CARACTERIZADO PORQUE R1 es metilo o etilo; R2 es metilo o etilo; o una sal del mismo aceptable para uso farmacéutico. 3.- Un compuesto de la reivindicación 1 CARACTERIZADO PORQUE tiene la fórmula IIa:4.- Un compuesto de la reivindicación 1 CARACTERIZADO PORQUE el compuesto es una sal de un compuesto de fórmula I aceptable para uso farmacéutico la:5.- Una composición farmacéutica CARACTERIZADA PORQUE comprende un vehículo aceptable para uso farmacéutico y un compuesto de cualquiera de las reivindicaciones 1 a 4.
CO08115666A 2006-04-25 2008-10-29 Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico CO6140054A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79470206P 2006-04-25 2006-04-25

Publications (1)

Publication Number Publication Date
CO6140054A2 true CO6140054A2 (es) 2010-03-19

Family

ID=38577470

Family Applications (1)

Application Number Title Priority Date Filing Date
CO08115666A CO6140054A2 (es) 2006-04-25 2008-10-29 Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico

Country Status (20)

Country Link
US (3) US7524965B2 (es)
EP (1) EP2010489B1 (es)
JP (1) JP2009541209A (es)
KR (1) KR20090005389A (es)
CN (1) CN101426764A (es)
AR (1) AR060647A1 (es)
AU (1) AU2007243481A1 (es)
BR (1) BRPI0710767A2 (es)
CA (1) CA2650530A1 (es)
CO (1) CO6140054A2 (es)
ES (1) ES2391584T3 (es)
IL (1) IL194334A0 (es)
MA (1) MA30556B1 (es)
MX (1) MX2008013555A (es)
NO (1) NO20084603L (es)
PE (1) PE20080094A1 (es)
RU (1) RU2008146383A (es)
TW (1) TW200811105A (es)
WO (1) WO2007127196A2 (es)
ZA (1) ZA200808817B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7528253B2 (en) * 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
MY149731A (en) * 2008-02-06 2013-10-14 Astrazeneca Ab Compounds
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
CA3180743A1 (en) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
CN114409556A (zh) * 2022-01-28 2022-04-29 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006635A1 (fr) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
WO1995021820A1 (fr) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2543858C (en) * 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2007528416A (ja) * 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
US7528253B2 (en) * 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510015A (ja) * 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
KR20090005389A (ko) 2009-01-13
NO20084603L (no) 2008-11-19
US8134006B2 (en) 2012-03-13
CN101426764A (zh) 2009-05-06
ES2391584T3 (es) 2012-11-28
EP2010489A2 (en) 2009-01-07
BRPI0710767A2 (pt) 2011-06-07
JP2009541209A (ja) 2009-11-26
US7524965B2 (en) 2009-04-28
WO2007127196A3 (en) 2007-12-21
US20090176833A1 (en) 2009-07-09
ZA200808817B (en) 2010-03-31
US7687521B2 (en) 2010-03-30
AU2007243481A1 (en) 2007-11-08
RU2008146383A (ru) 2010-05-27
PE20080094A1 (es) 2008-02-17
IL194334A0 (en) 2009-08-03
MA30556B1 (fr) 2009-07-01
US20070249675A1 (en) 2007-10-25
US20100137603A1 (en) 2010-06-03
CA2650530A1 (en) 2007-11-08
EP2010489B1 (en) 2012-08-22
TW200811105A (en) 2008-03-01
WO2007127196A2 (en) 2007-11-08
MX2008013555A (es) 2008-11-04
AR060647A1 (es) 2008-07-02

Similar Documents

Publication Publication Date Title
CO6140054A2 (es) Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
CL2009000815A1 (es) Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria.
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
AR061134A1 (es) Derivados de tioxantina
AR067770A1 (es) Derivados de tiazol y ditiazol para el tratamiento de diabetes
ECSP078003A (es) Inhibidores de aspartil proteasas
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
RS52700B (en) SUBSTITUTED OXINDOL DERIVATIVE AND ITS USE AS A VASOPRESIN RECEPTOR LIGAND
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
CL2008000836A1 (es) Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
AR073524A1 (es) Piridopirimidinonas inhibidores de pi3k a y m tor
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
CR20110250A (es) Antagonistas de los receptores de la melacortina
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
ECSP109900A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
ATE502936T1 (de) 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
AR056175A1 (es) Compuestos de cromano como antagonistas de 5-ht1b